Laurus Labs Q2 Net Profit jumps 126% to Rs 441-Cr
Hyderabad, Oct 29 (TNT) : Laurus Labs Ltd on Thursday reported a 126 per cent year-on-year increase in net profit to Rs 441 crore for the second quarter of FY27, compared with Rs 195 crore in the corresponding quarter of the previous financial year, driven by strong revenue growth and improved operating margins.
Revenue for the July-September quarter rose 33 per cent to Rs 2,206 crore from Rs 1,653 crore a year earlier, while EBITDA increased 78 per cent to Rs 762 crore from Rs 429 crore, the Hyderabad based pharmaceutical company said in a release.
EBITDA margin improved to 34.5 per cent from 26 per cent, while gross margin rose to 63 per cent from 59.9 per cent, according to the company’s financial results.
Profit before tax (PBT) more than doubled to Rs 592 crore from Rs 270 crore, registering a 119 per cent increase. Diluted earnings per share rose to Rs 8.2 from Rs 3.6.
For the first half of FY27, Laurus Labs reported a 31 per cent increase in revenue to Rs 4,233 crore, compared with Rs 3,223 crore in the corresponding period last year.
EBITDA rose 72 per cent to Rs 1,406 crore from Rs 818 crore, while net profit increased 126 per cent to Rs 809 crore from Rs 358 crore.
PBT more than doubled to Rs 1,073 crore from Rs 494 crore.
EBITDA margin for the first half improved to 33.2 per cent from 25.4 per cent, while gross margin increased to 62.9 per cent from 59.6 per cent.
Laurus Labs founder and CEO Satyanarayana Chava said the company had operationalised its first commercial-scale peptide plant in Visakhapatnam, with capacity expansion underway to meet rising demand for peptide therapeutics.
The company had also invested in oligonucleotide and peptide-resin technologies to strengthen its contract development and manufacturing organisation (CDMO) capabilities, he said.
Executive Director and Chief Financial Officer V.V. Ravi Kumar attributed the performance to sustained momentum in the CDMO and affordable medicines divisions, improved capacity utilisation and a favourable business mix.
The company also advanced capital expenditure milestones across its growth projects, with investments focused on supporting near- and long-term expansion, he added.
TNT TS
